June 6, 2025 – A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events and inpatient admissions. This is the first retrospective trial to evaluate the clinical impact of GLP-1 RAs for patients with moderate PAD. Findings were presented during the Society for Vascular  Surgery’s Vascular Annual Meeting, in New Orleans, Louisiana. 

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons, finds that Medicare patients with atrial fibrillation (AF) who undergo surgical ablation during isolated coronary artery bypass grafting (CABG) live longer than those who do not, offering compelling support for clinical guidelines that recommend this procedure but are too often not followed in practice.

May 30, 2025 — BiVACOR, a clinical-stage medical device company developing the world’s first titanium Total Artificial Heart (TAH), announced that its device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease. This therapy is available for patients whose mitral valves are not functioning properly due to severe mitral annular calcification (MAC), a buildup of calcium within the ring-like structure (known as an annulus) that supports the mitral valve.

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities with long-term economic or social challenges still face barriers to cutting-edge therapies such as gene editing, according to a 2020 American Heart Association presidential advisory.